123 related articles for article (PubMed ID: 24283833)
1. HER2 and immunotherapy using monoclonal antibodies in colorectal cancer.
Nazemalhosseini Mojarad E; Kuppen PJ
Immunotherapy; 2013 Dec; 5(12):1267-9. PubMed ID: 24283833
[No Abstract] [Full Text] [Related]
2. Tumor immunology top 10 list.
Finn OJ
Immunol Rev; 2008 Apr; 222():5-8. PubMed ID: 18363991
[No Abstract] [Full Text] [Related]
3. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
Med Lett Drugs Ther; 2013 Sep; 55(1425):75-6. PubMed ID: 24662957
[No Abstract] [Full Text] [Related]
4. Hormone receptor status affects locoregional control in HER2-positive breast cancer treated with trastuzumab.
Barton MK
CA Cancer J Clin; 2012; 62(5):281-2. PubMed ID: 22847535
[No Abstract] [Full Text] [Related]
5. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
Paik S; Kim C; Wolmark N
N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
[No Abstract] [Full Text] [Related]
6. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
Nielsen DL; Kümler I; Palshof JA; Andersson M
Breast; 2013 Feb; 22(1):1-12. PubMed ID: 23084121
[TBL] [Abstract][Full Text] [Related]
7. Anti-HER-2 anti-CD3 bi-specific antibodies inhibit growth of HCT-116 colorectal carcinoma cells in vitro and in vivo.
Ren H; Li J; Liu JJ; Guo HL; Jiang T
Asian Pac J Cancer Prev; 2012; 13(6):2795-8. PubMed ID: 22938461
[TBL] [Abstract][Full Text] [Related]
8. Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer.
Roukos DH
J Clin Oncol; 2010 Jun; 28(17):e279-80; author reply e282-3. PubMed ID: 20406920
[No Abstract] [Full Text] [Related]
9. [Predictive value of Her2/neu expression/amplification for the targeted treatment of breast cancer].
Lehr HA; Schaefer SC; Delaloye JF
Rev Med Suisse; 2009 Jul; 5(211):1525-9. PubMed ID: 19694364
[TBL] [Abstract][Full Text] [Related]
10. Cardiac toxicity monitoring for HER2-positive breast cancer patients undergoing trastuzumab therapy: are we doing enough?
Gujral DM; Lloyd G; Bhattacharyya S
Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):446-7. PubMed ID: 23583229
[No Abstract] [Full Text] [Related]
11. Herceptin.
Shepard HM; Jin P; Slamon DJ; Pirot Z; Maneval DC
Handb Exp Pharmacol; 2008; (181):183-219. PubMed ID: 18071947
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of resistance to HER2 target therapy.
Tortora G
J Natl Cancer Inst Monogr; 2011; 2011(43):95-8. PubMed ID: 22043051
[TBL] [Abstract][Full Text] [Related]
13. Cancer stem cell hypothesis and trastuzumab in HER2-negative tumors.
Tuma RS
J Natl Cancer Inst; 2012 Jul; 104(13):968-9. PubMed ID: 22745473
[No Abstract] [Full Text] [Related]
14. Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets.
Cho WC; Roukos DH
Expert Rev Anticancer Ther; 2013 Jan; 13(1):5-8. PubMed ID: 23259420
[No Abstract] [Full Text] [Related]
15. MMR deficiency may lead to a high immunogenicity and then an improvement in anti-PD-1 efficacy for metastatic colorectal cancer.
Aguiar PN; Tadokoro H; Forones NM; de Mello RA
Immunotherapy; 2015; 7(11):1133-4. PubMed ID: 26568256
[No Abstract] [Full Text] [Related]
16. [Chemo- and immunotherapy of colorectal cancer].
Klein HO
Internist (Berl); 1991 Jun; 32(6):348-53. PubMed ID: 1880013
[No Abstract] [Full Text] [Related]
17. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.
Bang YJ
J Clin Gastroenterol; 2012 Sep; 46(8):637-48. PubMed ID: 22751336
[TBL] [Abstract][Full Text] [Related]
18. Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer.
Bedard PL; Piccart-Gebhart MJ
Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S157-65. PubMed ID: 19158036
[TBL] [Abstract][Full Text] [Related]
19. Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease.
Ferretti G; Fabi A; Felici A; Papaldo P
J Clin Oncol; 2010 Jul; 28(20):e337; author reply e338-9. PubMed ID: 20479395
[No Abstract] [Full Text] [Related]
20. Why your preferred targeted drugs may become unaffordable.
Piccart MJ
Cancer Res; 2013 Oct; 73(19):5849-51. PubMed ID: 24062313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]